—Cambridge-based Forma Therapeutics nabbed $25.5 million in a Series B venture round led by new backer Lilly Ventures, and joined by the Novartis Option Fund and Bio One Capital of Singapore. Forma CEO Steven Tregay told Luke about the company’s plans to invest in its own drug pipeline, as well as continuing to serve the many pharma partners interested in its drug-discovery engine, which aims in part to find drugs that hit previously inaccessible targets.